Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
- PMID: 7768629
- DOI: 10.1002/ijc.2910610502
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
Abstract
Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA mediates its action while attached to a membrane-bound receptor (uPAR). In this investigation we show that uPAR levels correlate with uPA levels in human breast cancers. uPAR levels, however, do not correlate with other components of the plasminogen activator system such as tissue-type plasminogen activator (t-PA), PAI-I or PAI-2. In addition, uPAR levels showed no correlation with tumor size, axillary-node status or estrogen-receptor status. On the basis of an optimum cut-off point, patients with breast cancers containing high levels of uPAR had a worse prognosis than patients with low levels of the receptor. However, as a prognostic marker in breast cancer, uPAR was not as strong as uPA. Our results are consistent with data from model systems suggesting that both uPA and uPAR are necessary for metastasis.
Similar articles
-
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.Int J Mol Med. 2000 Sep;6(3):301-5. Int J Mol Med. 2000. PMID: 10934293
-
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.Clin Breast Cancer. 2002 Jun;3(2):138-46. doi: 10.3816/CBC.2002.n.018. Clin Breast Cancer. 2002. PMID: 12123538
-
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.Cancer Res. 2000 Feb 1;60(3):636-43. Cancer Res. 2000. PMID: 10676647
-
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.Clin Biochem. 2004 Jul;37(7):541-8. doi: 10.1016/j.clinbiochem.2004.05.013. Clin Biochem. 2004. PMID: 15234235 Review.
-
Urokinase-type plasminogen activator system and breast cancer (Review).Oncol Rep. 2005 Jul;14(1):105-12. Oncol Rep. 2005. PMID: 15944776 Review.
Cited by
-
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X. Am J Pathol. 2000. PMID: 10666386 Free PMC article.
-
Plasminogen activator inhibitor type 2 in breast cancer.Br J Cancer. 1997;76(5):622-7. doi: 10.1038/bjc.1997.435. Br J Cancer. 1997. PMID: 9303361 Free PMC article.
-
Expression of alphav integrins and vitronectin receptor identity in breast cancer cells.Br J Cancer. 1998 Feb;77(4):530-6. doi: 10.1038/bjc.1998.86. Br J Cancer. 1998. PMID: 9484807 Free PMC article.
-
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.Mol Cell Biochem. 1999 Sep;199(1-2):189-200. doi: 10.1023/a:1006914800447. Mol Cell Biochem. 1999. PMID: 10544967
-
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.Br J Cancer. 1998 Jul;78(1):88-95. doi: 10.1038/bjc.1998.447. Br J Cancer. 1998. PMID: 9662256 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous